Clinical Trial Update: Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

View source ↗

Summary

Ongoing clinical trial evaluating zanubrutinib in combination with rituximab for marginal zone lymphoma; recruitment is currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Marginal Zone Lymphoma | Status: RECRUITING